A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Official Title

Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies


This is a phase 2 study (the second phase in testing a new drug) to see how useful an investigational drug called afatinib is in patients with advanced cancer with changes in the HER gene. Afatinib is a drug that is approved by Health Canada for the treatment of advanced lung cancer with changes in the HER gene. Afatinib works by attaching to and blocking a protein called HER from working. HER is an important protein that contributes to the growth of cancer cells.

Trial Description

Primary Outcome:

  • Number of patients with complete response
  • Number of patients with partial response
Secondary Outcome:
  • Number of Grade 1 side effects
  • Number of Grade 2 side effects
  • Number of Grade 3 side effects
  • Number of Grade 4 side effects
  • Timeframe of Progression Free Survival

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society